Zymeworks BC Inc.
Healthcare · Pharmaceutical Preparations · A1 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | $26.7M | $39.0M | $29.5M | $53.0M | $51.8M | $11.0M |
| Operating income | −$215.6M | −$187.5M | −$151.3M | −$33.4M | −$9.5M | −$37.9M |
| Net income | −$211.8M | −$180.6M | −$145.4M | −$36.6M | −$10.4M | −$33.8M |
| Total assets | $389.1M | $538.4M | $368.2M | $244.5M | $132.0M | — |
| Total liabilities | $140.0M | $128.5M | $122.5M | $64.0M | $15.5M | — |
| Equity | $249.1M | $409.9M | $245.7M | $180.5M | $116.4M | $9.0M |
| EPS (diluted) | $-4.61 | $-3.58 | $-3.83 | $-1.26 | $-0.64 | $-2.65 |
| Shares out. | 46.1M | 45.5M | 32.0M | 32.0M | 25.4M | 12.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- −808.2%
- Net margin
- −794.0%
- Return on equity
- −85.0%
- Return on assets
- −54.4%
- Return on capital (ROCE)
- −68.0%
- Liabilities / assets
- 36.0%
- Debt / equity
- 0.56×
- Book value / share
- $5.40
- Revenue growth (YoY)
- −31.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- -3.93distress
- Accruals / assets
- −5.0%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-12A Study of ZW191 in Participants With Solid Tumors
- Phase 1Recruitingreadout ~2027-09A Study of ZW251 in Participants With Advanced Solid Tumors
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Josephson NeilOfficer — Chief Medical Officer | Nov 10, 2022 | Option exercise | 5,885 | $0.00 |
| Josephson NeilOfficer — Chief Medical Officer | Jul 5, 2022 | Grant | 1,525 | $4.51 |
| Klompas Neil AOfficer — Chief Operating Officer | Jul 5, 2022 | Grant | 1,525 | $4.51 |
| Klompas Neil AOfficer — Chief Operating Officer | Mar 10, 2022 | Option exercise | 2,500 | $0.00 |
| Josephson NeilOfficer — Chief Medical Officer | Mar 10, 2022 | Option exercise | 729 | $0.00 |
| Josephson NeilOfficer — Chief Medical Officer | Jan 7, 2022 | Buy | 1,400 | $14.27 |
| Josephson NeilOfficer — Chief Medical Officer | Jan 7, 2022 | Grant | 65 | $13.94 |
| Polverino Anthony J.Officer — Chief Scientific Officer | Jan 7, 2022 | Grant | 74 | $13.94 |
| Klompas Neil AOfficer — Chief Operating Officer & CFO | Jan 7, 2022 | Grant | 277 | $13.94 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreementOct 21, 2022
- Entered a material agreement · Regulation FD disclosureOct 19, 2022
- Amended charter or bylaws · Other material eventOct 18, 2022
- Entered a material agreement · Terminated a material agreement · Delisting / listing-standard notice · Modified shareholder rights · Other material eventOct 12, 2022
- Shareholder vote · Regulation FD disclosureOct 11, 2022
- Regulation FD disclosureOct 4, 2022
- Regulation FD disclosureOct 3, 2022
- Regulation FD disclosureSep 26, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2023
- SC 13G/ASEC SCHEDULE 13GFeb 6, 2023
- 4FORM 4 SUBMISSIONNov 14, 2022
- 15-12GTX15-12GOct 24, 2022
- 8-KOct 21, 2022
- 8-KOct 19, 2022
- 8-KOct 18, 2022
- S-8 POSOct 13, 2022
- S-8 POSOct 13, 2022
- S-8 POSOct 13, 2022
- S-8 POSOct 13, 2022
- POSASROct 13, 2022
- 25-NSEOct 13, 2022
- 25-NSEOct 13, 2022
- 425Oct 12, 2022